Filed in archive
Cancer
, Studies
, Treatment
by Gloria Gamat on November 13, 2007
According to a study pre-published online in Blood, the official journal of the American Society of Hematology, the drug Gleevec® (imatinib mesylate) proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML).
According to Hagop Kantarjian, MD, the lead author on the study and Chairman and Professor of the Leukemia Department at the University of Texas M.D. Anderson Cancer Center:
Gleevec® (imatinib mesylate) - a product of Novartis - when first approved for CML has since been the standard of care for the disease.
Find more details from the American Society of Hematology.
[Photo Credit. www.drugs.com]
According to Hagop Kantarjian, MD, the lead author on the study and Chairman and Professor of the Leukemia Department at the University of Texas M.D. Anderson Cancer Center:
"The long-term follow-up results of imatinib in CML post interferon failure reassure us of the high efficacy of the drug and its safety.
With a six-year follow-up, the estimated six-year survival rate is 76 percent. In historical data, after interferon failure the average survival was about three to four years."
Gleevec® (imatinib mesylate) - a product of Novartis - when first approved for CML has since been the standard of care for the disease.
Find more details from the American Society of Hematology.
[Photo Credit. www.drugs.com]
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/101967
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Gleevec®, Proven Safe and Effective Over The Long Term:
|
Rating: 7.33 out of 6 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
